New Stock News | RECBIO-B(02179) Domestic Unlisted Shares "Fully Circulated" Approved by China Securities Regulatory Commission

On January 28, the International Cooperation Department of the China Securities Regulatory Commission issued a "Notice of Filing for 'Full Circulation' of Unlisted Shares of Jiangsu Recbio Biotechnology Co., Ltd. domestically". 28 shareholders of RECBIO-B (02179) intend to convert a total of 141,953,489 domestically unlisted shares into internationally listed shares and list them for circulation on the Hong Kong Stock Exchange. On December 30, Recbio Biotechnology announced that the new drug application for REC610, a recombinant herpes zoster vaccine, with a new adjuvant had been officially accepted by the National Medical Products Administration Drug Evaluation Center. REC610 carries the company's independently developed BFA01 adjuvant, which can promote the body to produce high levels of VZV glycoprotein E (gE) specific CD4+T cells and antibodies. Currently, the only globally available recombinant herpes zoster vaccine with a new adjuvant is Shingrix by GlaxoSmithKline. Appendix: "Full Circulation" shareholder names and conversion quantities.